Tivozanib – Uses, Dosage, Side Effects, Interaction Tivozanib is a Kinase Inhibitor. The mechanism of action of tivozanib is as a Tyrosine Kinase Inhibitor. Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2, and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis, and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021, by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies. Tivozanib Hydrochloride is the hydrochloride salt of tivozanib, an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2, and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis, and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.9 Mechanism of Action The VHL mutation-HIF upregulation-VEGF transcription is the main pathway implicated in the growth of renal cell carcinoma. Vascular endothelial growth factor receptors (VEGFR receptors) are important targets for tyrosine kinase inhibitors, which halt the growth of tumors. Tivozanib is a tyrosine kinase inhibitor that exerts its actions by inhibiting the phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3 and inhibits other kinases such as c-kit and platelet-derived growth factor beta (PDGFR β). The above actions inhibit tumor growth and progression, treating renal cell carcinoma. Tivozanib inhibits growth factor receptors, treating renal cell carcinoma. In mice and rats, tivozanib inhibits tumor angiogenesis, tumor growth, and vascular permeability. Tivozanib was shown to frequently cause hypertension in clinical trials; hypertension must be managed before initiating therapy. Cardiac QT segment prolongation was reported in a tivozanib cardiac safety study, however, the reactions were not considered clinically serious. In clinical studies, levels of serum soluble VEGFR2 (sVEGFR2) decreased with time and this effect increased with tivozanib exposure, and sVEGFR2 may serve as a pharmacodynamic marker of VEGFR inhibition. Indications Tivozanib is approved in the USA for the treatment of relapsed or refractory renal cell carcinoma in adult patients who have undergone two or more systemic therapies. In the UK and other countries, is indicated as the first-line therapy of adults with advanced renal cell carcinoma (RCC) and VEGFR and mTOR pathway inhibitor-naïve patients after disease progression following one previous treatment with cytokine therapy for advanced disease. Fotivda is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma. Tivozanib hydrochloride is approved to treat: Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used in adults whose disease has relapsed (come back) or is refractory (does not respond to treatment) after at least two other types of systemic therapy. Tivozanib hydrochloride is also being studied in the treatment of other types of cancer. Tivozanib is used for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies Tivozanib is a kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease. Use in Cancer Tivozanib hydrochloride is approved to treat: Renal cell carcinoma (a type of kidney cancer) is advanced. It is used in adults whose disease has relapsed (come back) or is refractory (does not respond to treatment) after at least two other types of systemic therapy. Tivozanib hydrochloride is also being studied in the treatment of other types of cancer. Contraindications overactive thyroid gland a condition with low thyroid hormone levels an increased risk of bleeding high blood pressure a heart attack chronic heart failure a stroke nephrotic syndrome, a type of kidney disorder recent operation elevation of proteins in the urine impaired wound healing pregnancy a patient who is producing milk and breastfeeding a type of brain disorder called posterior reversible encephalopathy syndrome Dosage Strengths: 890 mcg; 1340 mcg Renal Cell Carcinoma 1.34 mg orally once a day for 21 days followed by 7 days off (28-day cycle) until disease progression or unacceptable toxicity For adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following 2 or more prior systemic therapies Renal Dose Adjustments Mild/moderate/severe renal impairment (CrCl 15 to 89 mL/min): No adjustment recommended. End-stage renal disease: Data not available Liver Dose Adjustments Mild (total bilirubin less than or equal to the upper limit of normal [ULN] with AST greater than ULN or total bilirubin greater than 1 to 1.5 x ULN with any AST) hepatic impairment: No adjustment recommended. Moderate (total bilirubin greater than 1.5 to 3 x ULN with any AST) hepatic impairment: Reduce dose to 0.89 mg orally once a day for 21 days followed by 7 days off (28-day cycle) Severe (total bilirubin greater than 3 to 10 x ULN with any AST) hepatic impairment: Data not available Dose Adjustments Initiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction. Recommended dose modifications: Reduce the dose to 0.89 mg orally once a day for 21 days followed by 7 days off for a 28-day cycle. Dose Modifications for Adverse Reactions: HYPERTENSION: Grade 3: Withhold therapy for Grade 3 that persists despite antihypertensive therapy; resume at reduced dose when hypertension is controlled at less than or equal to Grade 2. Grade 4: Permanently discontinue therapy. CARDIAC FAILURE: Grade 3: Withhold until improvement to Grade 0, 1, or baseline; resume at reduced dose or discontinue therapy based on severity and persistence of adverse reaction. Grade 4: Permanently discontinue therapy. ARTERIAL THROMBOEMBOLIC EVENTS: Any Grade: Permanently discontinue therapy. HEMORRHAGIC EVENTS: Grade 3 or 4: Permanently discontinue therapy. PROTEINURIA: Two grams or greater proteinuria in 24 hours: Withhold therapy until less than or equal to 2 grams of proteinuria in 24 hours; resume at a reduced dose; permanently discontinue for nephrotic syndrome. REVERSE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME: Any Grade: Permanently discontinue therapy. OTHER ADVERSE REACTIONS: Persistent or intolerable Grade 2 or 3 adverse reaction: Grade 4 laboratory abnormality: Withhold therapy until improvement to Grade 0, 1, or baseline; resume at a reduced dose. Grade 4 adverse reaction: Permanently discontinue therapy. Administration advice: This drug can be taken with or without food. Swallow the capsule whole with a glass of water. Swallow the capsule whole; do not open, crush, or chew the capsule. If a dose is missed, the next dose should be taken at the next scheduled time; do not take two doses at the same time. In the case of vomiting, a replacement dose should not be taken; the next dose should be taken at the next scheduled time. Side Effects The Most Common diarrhea nausea vomiting fatigue loss of appetite weight loss voice hoarseness back pain mouth sores cough shortness of breath unusual bruising or bleeding bloody or black and tarry stools blood in urine vomiting or coughing up blood bleeding from gums seizures, headaches, vision changes, or confusion redness, swelling, and pain on hands and/or feet confusion, headache, dizziness, chest pain, or shortness of breath shortness of breath or swelling of ankles chest pain or pressure; numbness or weakness on one side of body; pain in arms, back, neck or jaw; difficulty talking; shortness of breath; sudden severe headache; vision changes; or swelling in arms or legs More common Agitation back pain black, tarry stools bleeding from the rectum or bloody stools bleeding gums blood in the urine bloody nose blurred vision change in consciousness cloudy urine collection of blood under the skin confusion confusion as to time, place, or person constipation coughing or spitting up blood decreased urine output deep, dark purple bruise depressed mood depression difficulty in swallowing dilated neck veins dizziness drowsiness dry skin and hair enlarged pupils feeling cold fever hair loss heavy nonmenstrual vaginal bleeding hoarseness or husky voice holding false beliefs that cannot be changed by fact hostility increased menstrual flow or vaginal bleeding increased sensitivity of the eyes to light increased sweating, possibly with fever or cold, clammy skin irregular breathing irregular heartbeat irritability itching lethargy loss of consciousness muscle cramps, stiffness, twitching nausea nervousness nosebleeds pain or discomfort in the arms, jaw, back, or neck pain, redness, or swelling in the arm or leg pains in the chest, groin, or legs, especially calves of the legs paralysis pounding in the ears prolonged bleeding from cuts red or dark brown urine red or black, tarry stools seeing, hearing, or feeling things that are not there seizures sensitivity to heat severe chest pain severe headache slow or fast heartbeat sore throat stiff or sore neck stupor sudden loss of coordination sudden onset of slurred speech sudden onset of trouble breathing for no apparent reason sudden vision changes swelling of the face, fingers, feet, or lower legs tightness in the chest trouble breathing trouble healing trouble sleeping unusual excitement, nervousness, or restlessness unusual tiredness or weakness voice changes vomiting vomiting of blood or material that looks like coffee grounds weight gain or loss Rare Blistering, crusting, irritation, itching, or reddening of the skin blistering, peeling, loosening of the skin cracked, dry, scaly skin cough decreased appetite diarrhea dry, flaky, scaling skin on the scalp, eyebrows, near the ears, and around the nose increased sensitivity of skin to sunlight joint or muscle pain lack or loss of strength rash with flat lesions or small raised lesions on the skins red, irritated eyes redness or other discoloration of skin severe sunburn skin rash, encrusted, scaly and oozing sores, ulcers, or white spots in the mouth or on the lips swelling swelling or inflammation of the mouth Drug interactions DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Tivozanib. Abemaciclib Tivozanib may decrease the excretion rate of Abemaciclib which could result in a higher serum level. Abrocitinib The serum concentration of Tivozanib can be increased when it is combined with Abrocitinib. Acetaminophen The metabolism of Tivozanib can be increased when combined with Acetaminophen. Afatinib Tivozanib may decrease the excretion rate of Afatinib which could result in a higher serum level. Allopurinol Tivozanib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Alpelisib The metabolism of Tivozanib can be increased when combined with Alpelisib. Ambrisentan The serum concentration of Tivozanib can be increased when it is combined with Ambrisentan. Aminoglutethimide The metabolism of Tivozanib can be increased when combined with Aminoglutethimide. Amiodarone The serum concentration of Tivozanib can be increased when it is combined with Amiodarone. Amobarbital The metabolism of Tivozanib can be increased when combined with Amobarbital. Amprenavir The metabolism of Tivozanib can be increased when combined with Amprenavir. Apalutamide The metabolism of Tivozanib can be increased when combined with Apalutamide. Apixaban Tivozanib may decrease the excretion rate of Apixaban which could result in a higher serum level. Armodafinil The metabolism of Tivozanib can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Tivozanib can be increased when it is combined with Arsenic trioxide. Artemether The metabolism of Tivozanib can be increased when combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Articaine. Asciminib The serum concentration of Tivozanib can be increased when it is combined with Asciminib. Asunaprevir The metabolism of Tivozanib can be increased when combined with Asunaprevir. Avanafil The serum concentration of Tivozanib can be increased when it is combined with Avanafil. Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Tivozanib. Axitinib The serum concentration of Axitinib can be increased when it is combined with Tivozanib. Beclomethasone The metabolism of Tivozanib can be increased when combined with Beclomethasone dipropionate. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Tivozanib. Belinostat The serum concentration of Tivozanib can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Tivozanib can be increased when it is combined with Belumosudil. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Tivozanib. Benzocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Benzyl alcohol. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Tivozanib. Betamethasone The metabolism of Tivozanib can be increased when combined with Betamethasone. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Tivozanib. Bexarotene The metabolism of Tivozanib can be increased when combined with Bexarotene. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Tivozanib. Bisoprolol The serum concentration of Tivozanib can be increased when it is combined with Bisoprolol. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Tivozanib. Bosentan The metabolism of Tivozanib can be increased when combined with Bosentan. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Tivozanib. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Tivozanib. Brigatinib The metabolism of Tivozanib can be increased when combined with Brigatinib. Budesonide The metabolism of Tivozanib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Butacaine. Butalbital The metabolism of Tivozanib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Tivozanib. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Tivozanib. Calcitriol The metabolism of Tivozanib can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Tivozanib can be increased when it is combined with Canagliflozin. Capmatinib The serum concentration of Tivozanib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Capsaicin. Carbamazepine The metabolism of Tivozanib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Tivozanib. Carfilzomib The serum concentration of Tivozanib can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Tivozanib can be increased when it is combined with Carvedilol. Cefradine The metabolism of Tivozanib can be increased when combined with Cefradine. Celecoxib Tivozanib may decrease the excretion rate of Celecoxib which could result in a higher serum level. Cenobamate The metabolism of Tivozanib can be increased when combined with Cenobamate. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Tivozanib. Cerivastatin The metabolism of Tivozanib can be increased when combined with Cerivastatin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Chloroprocaine. Chlorphenesin The metabolism of Tivozanib can be increased when combined with Chlorphenesin. Chlorpromazine The metabolism of Tivozanib can be increased when combined with Chlorpromazine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Cinchocaine. Cladribine Tivozanib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The serum concentration of Tivozanib can be increased when it is combined with Clarithromycin. Clevidipine The metabolism of Tivozanib can be increased when combined with Clevidipine. Clobazam The metabolism of Tivozanib can be increased when combined with Clobazam. Clobetasol The metabolism of Tivozanib can be increased when combined with Clobetasol. Clobetasol The metabolism of Tivozanib can be increased when combined with Clobetasol propionate. Clofarabine Tivozanib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The serum concentration of Tivozanib can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Tivozanib can be increased when combined with Clofibrate. Clomifene The serum concentration of Tivozanib can be increased when it is combined with Clomifene. Clozapine The metabolism of Tivozanib can be increased when combined with Clozapine. Cobicistat The serum concentration of Tivozanib can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Tivozanib. Cocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Cocaine. Colchicine The serum concentration of Tivozanib can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Tivozanib can be increased when it is combined with Conivaptan. Conjugated Tivozanib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib Tivozanib may decrease the excretion rate of Copanlisib which could result in a higher serum level. Corticotropin The metabolism of Tivozanib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Tivozanib can be increased when combined with Cortisone acetate. Crizotinib The serum concentration of Tivozanib can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Tivozanib can be increased when it is combined with Curcumin. Cyclophosphamide The metabolism of Tivozanib can be increased when combined with Cyclophosphamide. Cyclosporine The serum concentration of Tivozanib can be increased when it is combined with Cyclosporine. Dabigatran etexilate The serum concentration of Tivozanib can be increased when it is combined with Dabigatran etexilate. Dabrafenib The metabolism of Tivozanib can be increased when combined with Dabrafenib. Daclatasvir The serum concentration of Tivozanib can be increased when it is combined with Daclatasvir. Dacomitinib Tivozanib may decrease the excretion rate of Dacomitinib which could result in a higher serum level. Dactinomycin Tivozanib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Daptomycin The serum concentration of Tivozanib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tivozanib. Darolutamide Tivozanib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Darunavir The serum concentration of Tivozanib can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Tivozanib can be increased when it is combined with Dasabuvir. Dasatinib Tivozanib may decrease the excretion rate of Dasatinib which could result in a higher serum level. You Might Also Read Avanafil Indications Contraindications, Warning Daunorubicin Tivozanib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Deferasirox The metabolism of Tivozanib can be increased when combined with Deferasirox. Delafloxacin The metabolism of Tivozanib can be increased when combined with Delafloxacin. Desonide The metabolism of Tivozanib can be increased when combined with Desonide. Dexamethasone The metabolism of Tivozanib can be increased when combined with Dexamethasone. Dexamethasone acetate The metabolism of Tivozanib can be increased when combined with Dexamethasone acetate. Dicloxacillin The metabolism of Tivozanib can be increased when combined with Dicloxacillin. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Tivozanib. Digoxin The serum concentration of Digoxin can be increased when it is combined with Tivozanib. Diosmin The serum concentration of Tivozanib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Diphenhydramine. Dolutegravir Tivozanib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Donepezil Tivozanib may decrease the excretion rate of Donepezil which could result in a higher serum level. Doxorubicin Tivozanib may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Dronedarone The serum concentration of Tivozanib can be increased when it is combined with Dronedarone. Duvelisib Tivozanib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Dyclonine. Edoxaban The serum concentration of Tivozanib can be increased when it is combined with Edoxaban. Efavirenz The metabolism of Tivozanib can be increased when combined with Efavirenz. Elagolix The serum concentration of Tivozanib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Tivozanib can be increased when it is combined with Elbasvir. Eliglustat The serum concentration of Tivozanib can be increased when it is combined with Eliglustat. Enasidenib The metabolism of Tivozanib can be increased when combined with Enasidenib. Enfortumab vedotin The serum concentration of Enfortumab vedotin can be increased when it is combined with Tivozanib. Entrectinib The serum concentration of Tivozanib can be increased when it is combined with Entrectinib. Enzalutamide The metabolism of Tivozanib can be increased when combined with Enzalutamide. Erdafitinib The serum concentration of Tivozanib can be increased when it is combined with Erdafitinib. Ertugliflozin Tivozanib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The serum concentration of Tivozanib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tivozanib. Esketamine The metabolism of Tivozanib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Tivozanib can be increased when combined with Eslicarbazepine. Eslicarbazepine acetate The metabolism of Tivozanib can be increased when combined with Eslicarbazepine acetate. Estradiol acetate The metabolism of Tivozanib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Tivozanib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Tivozanib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Tivozanib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Tivozanib can be increased when combined with Estradiol valerate. Ethanol The metabolism of Tivozanib can be increased when combined with Ethanol. Ethotoin The metabolism of Tivozanib can be increased when combined with Ethotoin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Etidocaine. Etoposide The metabolism of Tivozanib can be increased when combined with Etoposide. Etravirine The metabolism of Tivozanib can be increased when combined with Etravirine. Everolimus The serum concentration of Tivozanib can be increased when it is combined with Everolimus. Ezetimibe Tivozanib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Favipiravir The serum concentration of Tivozanib can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Tivozanib can be increased when it is combined with Fedratinib. Felbamate The metabolism of Tivozanib can be increased when combined with Felbamate. Fexofenadine The serum concentration of Tivozanib can be increased when it is combined with Fexofenadine. Flibanserin The serum concentration of Tivozanib can be increased when it is combined with Flibanserin. Flucloxacillin The metabolism of Tivozanib can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Tivozanib can be increased when it is combined with Fluconazole. Flunisolide The metabolism of Tivozanib can be increased when combined with Flunisolide. Fluocinolone acetonide The metabolism of Tivozanib can be increased when combined with Fluocinolone acetonide. Fluorouracil Tivozanib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. Folic acid Tivozanib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Tivozanib. Formestane The metabolism of Tivozanib can be increased when combined with Formestane. Fosaprepitant The metabolism of Tivozanib can be increased when combined with Fosaprepitant. Fosphenytoin The metabolism of Tivozanib can be increased when combined with Fosphenytoin. Fostemsavir Tivozanib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Tivozanib. Gefitinib Tivozanib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Tivozanib. Gilteritinib The serum concentration of Gilteritinib can be increased when it is combined with Tivozanib. Glasdegib Tivozanib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Glecaprevir Tivozanib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Glyburide Tivozanib may decrease the excretion rate of Glyburide which could result in a higher serum level. Glycerol phenylbutyrate The metabolism of Tivozanib can be increased when combined with Glycerol phenylbutyrate. Grazoprevir The serum concentration of Tivozanib can be increased when it is combined with Grazoprevir. Griseofulvin The metabolism of Tivozanib can be increased when combined with Griseofulvin. Hydrocortamate The metabolism of Tivozanib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Tivozanib can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Tivozanib can be increased when combined with Hydrocortisone acetate. Hydrocortisone The metabolism of Tivozanib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Tivozanib can be increased when combined with Hydrocortisone probutate. Hydrocortisone The metabolism of Tivozanib can be increased when combined with Hydrocortisone succinate. Hydrocortisone valerate The metabolism of Tivozanib can be increased when combined with Hydrocortisone valerate. Idelalisib Tivozanib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Ifosfamide The metabolism of Tivozanib can be increased when combined with Ifosfamide. Imatinib Tivozanib may decrease the excretion rate of Imatinib which could result in a higher serum level. Imipramine The serum concentration of Imipramine can be increased when it is combined with Tivozanib. Indacaterol The serum concentration of Tivozanib can be increased when it is combined with Indacaterol. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tivozanib. Irinotecan Tivozanib may decrease the excretion rate of Irinotecan which could result in a higher serum level. Isavuconazole The metabolism of Tivozanib can be increased when combined with Isavuconazole. Isavuconazonium The metabolism of Tivozanib can be increased when combined with Isavuconazonium. Istradefylline The serum concentration of Tivozanib can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Tivozanib can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Tivozanib can be increased when it is combined with Ivacaftor. Ivermectin Tivozanib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Tivozanib can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Tivozanib can be increased when it is combined with Ixabepilone. Ketamine The metabolism of Tivozanib can be increased when combined with Ketamine. Ketoconazole The serum concentration of Tivozanib can be increased when it is combined with Ketoconazole. Lamivudine Tivozanib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lansoprazole The metabolism of Tivozanib can be increased when combined with Lansoprazole. Lapatinib The serum concentration of Tivozanib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Tivozanib. You Might Also Read What Is Toxins botulínica A? Indications, Contraindications Lasmiditan The serum concentration of Tivozanib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Tivozanib can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Lefamulin can be increased when it is combined with Tivozanib. Leflunomide Tivozanib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Tivozanib. Lenvatinib Tivozanib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Levobupivacaine. Levoketoconazole The serum concentration of Tivozanib can be increased when it is combined with Levoketoconazole. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tivozanib. Lidocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Lidocaine. Linagliptin The serum concentration of Tivozanib can be increased when it is combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tivozanib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Tivozanib. Lomitapide The serum concentration of Tivozanib can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Tivozanib can be increased when it is combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Tivozanib. Loperamide The serum concentration of Tivozanib can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Tivozanib can be increased when it is combined with Lopinavir. Lorlatinib The metabolism of Tivozanib can be increased when combined with Lorlatinib. Loxapine The serum concentration of Tivozanib can be increased when it is combined with Loxapine. Lumacaftor The metabolism of Tivozanib can be increased when combined with Lumacaftor. Lusutrombopag Tivozanib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Mannitol The serum concentration of Tivozanib can be increased when it is combined with Mannitol. Maribavir The serum concentration of Tivozanib can be increased when it is combined with Maribavir. Medroxyproge The metabolism of Tivozanib can be increased when combined with Medroxyprogesterone acetate. Mefloquine The serum concentration of Tivozanib can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Mepivacaine. Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Tivozanib. Methotrexate Tivozanib may decrease the excretion rate of Methotrexate which could result in a higher serum level. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tivozanib. Methylene blue The serum concentration of Tivozanib can be increased when it is combined with Methylene blue. Methylphenobarbital The metabolism of Tivozanib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Tivozanib can be increased when combined with Methylprednisolone. Metyrapone The metabolism of Tivozanib can be increased when combined with Metyrapone. Midostaurin The metabolism of Tivozanib can be increased when combined with Midostaurin. Mifepristone The metabolism of Tivozanib can be increased when combined with Mifepristone. Mirabegron The serum concentration of Tivozanib can be increased when it is combined with Mirabegron. Mitapivat The metabolism of Tivozanib can be increased when combined with Mitapivat. Mitotane The metabolism of Tivozanib can be increased when combined with Mitotane. Mitoxantrone Tivozanib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Modafinil The metabolism of Tivozanib can be increased when combined with Modafinil. Morphine The serum concentration of Tivozanib can be increased when it is combined with Morphine. Mycophenolate Tivozanib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Nafcillin The metabolism of Tivozanib can be increased when combined with Nafcillin. Neratinib The serum concentration of Tivozanib can be increased when it is combined with Neratinib. Netupitant The serum concentration of Tivozanib can be increased when it is combined with Netupitant. Nifedipine The metabolism of Tivozanib can be increased when combined with Nifedipine. Nilotinib Tivozanib may decrease the excretion rate of Nilotinib which could result in a higher serum level. Nintedanib The serum concentration of Tivozanib can be increased when it is combined with Nintedanib. Nitrofurantoin Tivozanib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norgestimate The metabolism of Tivozanib can be increased when combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Tivozanib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Tivozanib. Ombitasvir Tivozanib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Omeprazole The metabolism of Tivozanib can be increased when combined with Omeprazole. Oritavancin The metabolism of Tivozanib can be increased when combined with Oritavancin. Osimertinib Tivozanib may decrease the excretion rate of Osimertinib which could result in a higher serum level. Oxaliplatin Tivozanib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxcarbazepine The metabolism of Tivozanib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Oxetacaine. Oxiconazole The metabolism of Tivozanib can be increased when combined with Oxiconazole. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Oxybuprocaine. Ozanimod Tivozanib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Tivozanib can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Tivozanib can be increased when it is combined with Pacritinib. Palbociclib Tivozanib may decrease the excretion rate of Palbociclib which could result in a higher serum level. Paliperidone The serum concentration of Tivozanib can be increased when it is combined with Paliperidone. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Tivozanib. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tivozanib. Paritaprevir The serum concentration of Tivozanib can be increased when it is combined with Paritaprevir. Pazopanib Tivozanib may decrease the excretion rate of Pazopanib which could result in a higher serum level. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tivozanib. Pegvisomant The metabolism of Tivozanib can be increased when combined with Pegvisomant. Pentobarbital The metabolism of Tivozanib can be increased when combined with Pentobarbital. Perampanel The metabolism of Tivozanib can be increased when combined with Perampanel. Phenobarbital The metabolism of Tivozanib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Phenol. Phenylbutazone The metabolism of Tivozanib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Tivozanib can be increased when combined with Phenytoin. Pibrentasvir Tivozanib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pitavastatin Tivozanib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The metabolism of Tivozanib can be increased when combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Tivozanib. Ponatinib Tivozanib may decrease the excretion rate of Ponatinib which could result in a higher serum level. Posaconazole The serum concentration of Tivozanib can be increased when it is combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Tivozanib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Tivozanib. Pralatrexate Tivozanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The metabolism of Tivozanib can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Pramocaine. Pravastatin Tivozanib may decrease the excretion rate of Pravastatin which could result in a higher serum level. Prazosin Tivozanib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednicarbate The metabolism of Tivozanib can be increased when combined with Prednicarbate. Prednisolone The metabolism of Tivozanib can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Tivozanib can be increased when combined with Prednisolone acetate. Prednisolone phosphate The serum concentration of Prednisolone phosphate can be increased when it is combined with Tivozanib. Prilocaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Prilocaine. Primidone The metabolism of Tivozanib can be increased when combined with Primidone. Probenecid The metabolism of Tivozanib can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Procaine. Progesterone The metabolism of Tivozanib can be increased when combined with Progesterone. Propafenone The serum concentration of Tivozanib can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Propoxycaine. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tivozanib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Tivozanib. Quinidine The serum concentration of Tivozanib can be increased when it is combined with Quinidine. Quinine The metabolism of Tivozanib can be increased when combined with Quinine. Raloxifene Tivozanib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Ranolazine The serum concentration of Tivozanib can be increased when it is combined with Ranolazine. Regorafenib The serum concentration of Tivozanib can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Tivozanib. Reserpine The serum concentration of Tivozanib can be increased when it is combined with Reserpine. Revefenacin Tivozanib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Rifabutin The metabolism of Tivozanib can be increased when combined with Rifabutin. Rifampicin The metabolism of Tivozanib can be increased when combined with Rifampicin. Rifamycin The metabolism of Tivozanib can be increased when combined with Rifamycin. Rifapentine The metabolism of Tivozanib can be increased when combined with Rifapentine. Rifaximin The metabolism of Tivozanib can be increased when combined with Rifaximin. Riluzole Tivozanib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Tivozanib. Rimexolone The metabolism of Tivozanib can be increased when combined with Rimexolone. Riociguat Tivozanib may decrease the excretion rate of Riociguat which could result in a higher serum level. Ripretinib Tivozanib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Ritonavir Tivozanib may decrease the excretion rate of Ritonavir which could result in a higher serum level. Rivaroxaban Tivozanib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rofecoxib The metabolism of Tivozanib can be increased when combined with Rofecoxib. Rolapitant The serum concentration of Tivozanib can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Tivozanib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Ropivacaine. Rosuvastatin Tivozanib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Rucaparib Tivozanib may decrease the excretion rate of Rucaparib which could result in a higher serum level. Rufinamide The metabolism of Tivozanib can be increased when combined with Rufinamide. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Tivozanib. Sapropterin The serum concentration of Tivozanib can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Tivozanib can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Tivozanib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Tivozanib can be increased when combined with Sarilumab. Secobarbital The metabolism of Tivozanib can be increased when combined with Secobarbital. Selexipag The serum concentration of Tivozanib can be increased when it is combined with Selexipag. Selumetinib Tivozanib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sildenafil The serum concentration of Tivozanib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Tivozanib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Tivozanib can be increased when combined with Siltuximab. Simeprevir Tivozanib may decrease the excretion rate of Simeprevir which could result in a higher serum level. Simvastatin The serum concentration of Tivozanib can be increased when it is combined with Simvastatin. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Tivozanib. Sitagliptin The serum concentration of Tivozanib can be increased when it is combined with Sitagliptin. Sofosbuvir Tivozanib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Sorafenib Tivozanib may decrease the excretion rate of Sorafenib which could result in a higher serum level. Sotagliflozin The serum concentration of Tivozanib can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Tivozanib can be increased when it is combined with Sotorasib. St. John’s Wort The metabolism of Tivozanib can be increased when combined with St. John’s Wort. Stiripentol The excretion of Tivozanib can be decreased when combined with Stiripentol. Sulfasalazine Tivozanib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. Sulfinpyrazone The metabolism of Tivozanib can be increased when combined with Sulfinpyrazone. Sumatriptan Tivozanib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Suvorexant The serum concentration of Tivozanib can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Tivozanib can be increased when it is combined with Tacrolimus. Talazoparib Tivozanib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The metabolism of Tivozanib can be increased when combined with Tamoxifen. Tazemetostat Tivozanib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Technetium The serum concentration of Tivozanib can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Tivozanib can be increased when combined with Tecovirimat. Tegaserod Tivozanib may decrease the excretion rate of Tegaserod which could result in a higher serum level. Telaprevir The serum concentration of Tivozanib can be increased when it is combined with Telaprevir. Temsirolimus The serum concentration of Tivozanib can be increased when it is combined with Temsirolimus. Teniposide Tivozanib may decrease the excretion rate of Teniposide which could result in a higher serum level. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Tivozanib. Tenofovir disoproxil The serum concentration of Tivozanib can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Tivozanib can be increased when it is combined with Tepotinib. Terbinafine The metabolism of Tivozanib can be increased when combined with Terbinafine. Teriflunomide Tivozanib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Tivozanib. Testosterone The metabolism of Tivozanib can be increased when combined with Testosterone. Testosterone cypionate The metabolism of Tivozanib can be increased when combined with Testosterone cypionate. Testosterone enanthate The metabolism of Tivozanib can be increased when combined with Testosterone enanthate. Testosterone The metabolism of Tivozanib can be increased when combined with Testosterone undecanoate. Tetracaine The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Tetracaine. Tezacaftor The serum concentration of Tivozanib can be increased when it is combined with Tezacaftor. Thiopental The metabolism of Tivozanib can be increased when combined with Thiopental. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Tivozanib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tivozanib. Ticagrelor The serum concentration of Tivozanib can be increased when it is combined with Ticagrelor. Tipranavir The serum concentration of Tivozanib can be increased when it is combined with Tipranavir. Tocilizumab The metabolism of Tivozanib can be increased when combined with Tocilizumab. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Tivozanib. Topotecan Tivozanib may decrease the excretion rate of Topotecan which could result in a higher serum level. Toremifene The serum concentration of Tivozanib can be increased when it is combined with Toremifene. Trametinib The metabolism of Tivozanib can be increased when combined with Trametinib. Trastuzumab The serum concentration of Trastuzumab emtansine can be increased when it is combined with Tivozanib. Triamcinolone The metabolism of Tivozanib can be increased when combined with Triamcinolone. Trilaciclib Tivozanib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Tivozanib. Troglitazone The metabolism of Tivozanib can be increased when combined with Troglitazone. Tucatinib Tucatinib may decrease the excretion rate of Tivozanib which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Tivozanib. Umbralisib The serum concentration of Tivozanib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Tivozanib can be increased when it is combined with Umeclidinium. You Might Also Read Management of Drug Interactions, Types, Guideline Vandetanib The serum concentration of Tivozanib can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Tivozanib can be increased when it is combined with Vardenafil. Velpatasvir Tivozanib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. Vemurafenib The metabolism of Tivozanib can be increased when combined with Vemurafenib. Venetoclax Tivozanib may decrease the excretion rate of Venetoclax which could result in a higher serum level. Verapamil The serum concentration of Tivozanib can be increased when it is combined with Verapamil. Vinblastine The metabolism of Tivozanib can be increased when combined with Vinblastine. Vincristine Tivozanib may decrease the excretion rate of Vincristine which could result in a higher serum level. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Tivozanib. Vitamin E The metabolism of Tivozanib can be increased when combined with Vitamin E. Voclosporin The serum concentration of Tivozanib can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Tivozanib can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Tivozanib can be increased when it is combined with Voriconazole. Voxilaprevir Tivozanib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. Warfarin The metabolism of Tivozanib can be increased when combined with Warfarin. Zidovudine Tivozanib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zonisamide The serum concentration of Tivozanib can be increased when it is combined with Zonisamide. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on findings in animal studies and its mechanism of action, this drug can cause fetal harm when administered during pregnancy. This drug can harm a developing fetus. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Advise females of reproductive potential to use effective contraception during therapy and for 1 month after. Advise males with female partners of reproductive potential to use effective contraception during therapy and for 1 month after. This drug can impair fertility in females and males of reproductive potential. Lactation Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during therapy and for 1 month after the last dose. How should this medicine be used? Tivozanib comes as a capsule to take by mouth. It is usually taken once daily with or without food for the first 21 days of a 28-day cycle. The cycle may be repeated as recommended by your doctor. Take tivozanib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take tivozanib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the capsules whole with a glass of water; do not open them. Your doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with tivozanib. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before taking tivozanib, tell your doctor and pharmacist if you are allergic to tivozanib, aspirin, tartrazine (a yellow dye in some processed foods and drugs), any other medications, or any of the ingredients in tivozanib capsules. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: apalutamide (Erleada), carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Teril), enzalutamide (Xtandi), phenytoin (Dilantin, Phenytek), and rifampin (Rifadin, Rimactane, in Rifamate, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor and pharmacist what herbal products you are taking, especially St. John’s wort. Do not take St. John’s wort while taking tivozanib. tell your doctor if you have an unhealed wound or if you have or have ever had a bleeding problem; a blood clot; heart failure; a heart attack; high blood pressure; seizures; or heart, thyroid, kidney or liver disease. tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are taking tivozanib. If you are female, you will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your tivozanib treatment and for 1 month after your final dose. If you are male, you and your partner should use birth control to prevent pregnancy during your treatment with tivozanib and for 1 month after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. Tivozanib may decrease fertility in men and women. However, you should not assume that you or your partner cannot become pregnant. If you or your partner become pregnant while taking tivozanib, call your doctor. Tivozanib may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with tivozanib and for 1 month after your final dose. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking tivozanib. Your doctor will probably tell you to stop taking tivozanib at least 24 days before your scheduled surgery because it can affect wound healing. Your doctor will tell you when to start taking tivozanib again after your surgery. you should know that tivozanib may cause high blood pressure. Your blood pressure should be checked regularly while you are taking tivozanib. References https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-fotivda-tivozanib-adult-patients-relapsed-or-refractory https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/212904Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000AdminCorres.pdf https://www.cancer.gov/about-cancer/treatment/drugs/tivozanibhydrochloride https://pubchem.ncbi.nlm.nih.gov/compound/Tivozanib https://pubchem.ncbi.nlm.nih.gov/compound/Tivozanib-hydrochloride https://en.wikipedia.org/wiki/Tivozanib https://go.drugbank.com/drugs/DB11800 https://medlineplus.gov/druginfo/meds/a621018.html https://www.drugs.com/mtm/tivozanib.html https://www.mayoclinic.org/drugs-supplements/tivozanib-oral-route/side-effects/drg-20510803 https://www.webmd.com/drugs/2/drug-181152/tivozanib-oral/details/list-contraindications BindingDB https://www.bindingdb.org/rwd/bind/info.jsp CHEMBL1289494 https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331095 ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1289494/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads TIVOZANIB https://www.dgidb.org/drugs/TIVOZANIB DrugBank https://www.drugbank.ca/legal/terms_of_use Tivozanib https://www.drugbank.ca/drugs/DB11800 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license tivozanib https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Tivozanib http://idrblab.net/ttd/data/drug/details/D0W7JZ CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ Tivozanib https://commonchemistry.cas.org/detail?cas_rn=475108-18-0 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html https://chem.nlm.nih.gov/chemidplus/sid/0475108180 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources https://comptox.epa.gov/dashboard/DTXSID20963865 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking TIVOZANIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/172030934T ChEBI http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91327 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking TIVOZANIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C85444 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Fotivda (EMEA/H/C/004131) https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking TIVOZANIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Fotivda (Tivozanib Hydrochloride) https://www.cancer.gov/about-cancer/treatment/drugs/tivozanibhydrochloride NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html tivozanib https://rxnav.nlm.nih.gov/id/rxnorm/2534233 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AV9 PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=32064587-225180539 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=32064587-225180539 Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Tivozanib https://www.wikidata.org/wiki/Q7810457 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html tivozanib https://www.ncbi.nlm.nih.gov/mesh/67553176 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Protein Kinase Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68047428 KEGG https://www.kegg.jp/kegg/legal.html Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 390391032 https://pubchem.ncbi.nlm.nih.gov/substance/390391032 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More